Sign in

CIK 0001398733 · Non-accelerated filer<br>Smaller reporting company

Aquestive Therapeutics, Inc.

Sign in to watch
Ticker
AQST
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
208623253
Phone
908-941-1900
Business address
184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
Former names
MonoSol Rx, Inc.
Open-market buys, last 90 days
$99,331
in 1 filing
Open-market sales, last 90 days
$378,930
in 4 filings, $379K under 10b5-1 plans

Net −$279,599. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Barber Daniel −$333K President and CEO sold 11% of stake
  2. Daly Richard J +$99K Director 1 filing
  3. Korczynski Sherry −$46K Chief Commercial Officer sold 4% of stake
Date Insider Transaction Shares Price Value Owned after
2020-04-14 Schobel Alexander Mark Chief Innovation/Tech Officer Sale −40,000 $3.70 $148K 982,113
2020-03-31 Kendall Keith J CEO and President Option exercise +329 680,983
2020-03-31 Kendall Keith J CEO and President Shares withheld for taxes −99 $2.19 $217 680,884
2020-03-31 Kendall Keith J CEO and President Option exercise · Restricted Stock Units −329 333
2020-03-31 Schobel Alexander Mark Chief Innovation/Tech Officer Option exercise +329 1,062,210
2020-03-31 Schobel Alexander Mark Chief Innovation/Tech Officer Shares withheld for taxes −97 $2.19 $212 1,062,113
2020-03-31 Schobel Alexander Mark Chief Innovation/Tech Officer Option exercise · Restricted Stock Units −329 333
2020-03-16 Slatko Gary H SVP, Chief Medical Officer Grant or award · Non-Qualified Stock Option (right to buy) +50,000 50,000
2020-03-16 Wood Theresa SVP-HR and Org. Development Grant or award · Non-Qualified Stock Option (right to buy) +30,000 30,000
2020-03-16 Schobel Alexander Mark Chief Innovation/Tech Officer Grant or award · Non-Qualified Stock Option (right to buy) +70,000 70,000
2020-03-16 Maxwell John T. SVP-Chief Financial Officer Grant or award · Non-Qualified Stock Option (right to buy) +60,000 60,000
2020-03-16 Marshall Ken W. SVP, Chief Commercial Officer Grant or award · Non-Qualified Stock Option (right to buy) +45,400 45,400
2020-03-16 Kendall Keith J CEO and President Grant or award · Non-Qualified Stock Option (right to buy) +225,000 225,000
2020-03-16 Barber Daniel SVP-Chief Operating Officer Grant or award · Non-Qualified Stock Option (right to buy) +110,000 110,000
2020-03-16 BRAENDER LORI J SVP, General Counsel Purchase +14,000 $1.54 $22K 25,000
2020-03-16 BRAENDER LORI J SVP, General Counsel Grant or award · Non-Qualified Stock Option (right to buy) +60,000 60,000
2020-03-16 Boyd Peter E. SVP-Bus. Process & Info. Tech. Purchase +2,000 $1.50 $3K 52,239
2020-03-16 Boyd Peter E. SVP-Bus. Process & Info. Tech. Grant or award · Non-Qualified Stock Option (right to buy) +50,700 50,700
2020-02-29 Schobel Alexander Mark Chief Innovation/Tech Officer Option exercise +14,572 1,066,947
2020-02-29 Schobel Alexander Mark Chief Innovation/Tech Officer Shares withheld for taxes −5,066 $3.73 $19K 1,061,881

Page 16 of 24 · 462 trades